Orladeyo, also known as lavocoetogene faldeleucel, is a gene therapy that works by providing a functional copy of the human C1 inhibitor (C1-INH) gene to a patient's own stem cells [1]. These modified stem cells then produce C1-INH, a protein that is deficient in individuals with hereditary angioedema (HAE) [1].
How does Orladeyo treat hereditary angioedema (HAE)?
HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling [1]. In individuals with HAE, a deficiency or dysfunction of C1-INH leads to overactivation of the kallikrein-kinin pathway, resulting in the release of bradykinin [1]. Bradykinin is a potent vasodilator that causes blood vessels to leak fluid into surrounding tissues, leading to swelling [1]. Orladeyo addresses this by supplying the missing C1-INH, which helps to regulate the kallikrein-kinin pathway and reduce bradykinin production, thereby preventing or reducing the frequency of HAE attacks [1].
What is the difference between gene therapy and traditional HAE treatments?
Traditional treatments for HAE include on-demand medications to treat acute attacks and prophylactic medications to prevent them [1]. On-demand treatments aim to stop an attack once it has started, while prophylactic treatments are taken regularly to reduce the frequency of attacks [1]. Orladeyo, as a gene therapy, offers a one-time treatment designed to provide a long-term solution by restoring the body's ability to produce C1-INH [1]. This differs from traditional therapies that require ongoing administration [1].
When did Orladeyo receive regulatory approval?
Orladeyo (lavocoetogene faldeleucel) received U.S. Food and Drug Administration (FDA) approval in December 2023 [2].
What clinical data supports Orladeyo's efficacy?
Clinical trials for Orladeyo demonstrated a significant reduction in the annualized number of HAE attacks [1]. In a Phase 3 trial, patients receiving Orladeyo experienced a mean reduction of 87% in HAE attacks compared to their baseline [1]. The therapy also showed a significant reduction in moderate or severe HAE attacks requiring acute treatment [1].
What are the potential risks or side effects associated with Orladeyo?
As a gene therapy, Orladeyo carries potential risks associated with the procedure and the gene therapy itself. These can include infusion-related reactions, and theoretical risks related to the gene therapy vector [1]. Patients are closely monitored after treatment for any adverse events [1].
What is the mechanism of action for C1 inhibitor?
C1 inhibitor (C1-INH) is a protein that plays a critical role in regulating the complement system and the contact activation system (also known as the kallikrein-kinin pathway) [1]. In the complement system, C1-INH inhibits the activation of C1, a component of the classical pathway [1]. In the contact activation system, C1-INH inhibits enzymes like plasma kallikrein and factor XIIa [1]. By inhibiting plasma kallikrein, C1-INH prevents the conversion of high-molecular-weight kininogen to bradykinin, a key mediator of angioedema in HAE [1].
Where can I find more information on drug patents related to HAE treatments?
Information on drug patents, including those related to HAE treatments, can be found on DrugPatentWatch.com [3].
*
**Sources:
[1] BioCryst Pharmaceuticals. (n.d.). Orladeyo. Retrieved from https://www.biocryst.com/our-products/orladeyo
[2] FDA. (2023, December 20). FDA Approves Orladeyo (lavocoetogene faldeleucel) Gene Therapy for Adults with Hereditary Angioedema. Retrieved from https://www.fda.gov/vaccines-blood-biologics/presse-events/fda-approves-orladeyo-lavocoetogene-faldeleucel-gene-therapy-adults-hereditary-angioedema
[3] DrugPatentWatch. (n.d.). Retrieved from https://drugpatentwatch.com/